Zurich: Novartis said on Tuesday U.S. regulators have granted breakthrough therapy status for its investigational compound bimagrumab for the potential treatment of patients with sporadic inclusion body myositis (sIBM).The U.S. Food and Drug Administration (FDA) created the "breakthrough therapy" designation earlier this year for medicines deemed likely to demonstrate "substantial improvement" over existing drugs.
Firing across Pak-India border kills two
Ranchi: Violent clashes between JMM, BJP workers
SC refuses to postpone UPSC prelims
Mumbai: CCTV captures chain snatcher at Wadala station